EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSOTSG00005007306
Gene Symbol: GABRG3
3 Cross references
211 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSOTSG00005011865
Gene Symbol: GABRG3
1 Cross references
211 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSOTSG00005017492
Gene Symbol: GABBR1
1 Cross references
192 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSOTSG00005018415
Gene Symbol: GCGR
3 Cross references
179 Possible Orthologues:

Glucagon-Like Peptide 2 Receptor

Ensembl ID : ENSOTSG00005012283
Gene Symbol: LOC112233681
2 Cross references
198 Possible Orthologues:

Glucagon-Like Peptide 2 Receptor

Ensembl ID : ENSOTSG00005024962
Gene Symbol: LOC112233681
2 Cross references
198 Possible Orthologues:

Glucokinase

Ensembl ID : ENSOTSG00005027895
Gene Symbol: GCK
3 Cross references
205 Possible Orthologues:

Glucokinase-Like

Ensembl ID : ENSOTSG00005044327
Gene Symbol: LOC112248784
3 Cross references
205 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSOTSG00005022495
Gene Symbol: GBA1
3 Cross references
247 Possible Orthologues:

Glutamate Ionotropic Receptor Ampa Type Subunit 2

Ensembl ID : ENSOTSG00005046363
Gene Symbol: GRIA2
3 Cross references
224 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSOTSG00005047836
Gene Symbol: GRIN2B
1 Cross references
246 Possible Orthologues:

Glutamate Ionotropic Receptor Nmda Type Subunit 2b

Ensembl ID : ENSOTSG00005001284
Gene Symbol: GRIN2B
1 Cross references
247 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).